In CD4+ and CD8+ T cells and leukemic cells, TIM3 overexpression may lead to poor response and relapse in patients; therefore, TIM3 inhibitors are currently being investigated as potential AML treatments. Here, HAVCR2 is linked to acute myeloid leukemia.